Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

Summary: Background: The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Bruna Oriol-Tordera, Anna Esteve-Codina, María Berdasco, Míriam Rosás-Umbert, Elena Gonçalves, Clara Duran-Castells, Francesc Català-Moll, Anuska Llano, Samandhy Cedeño, Maria C. Puertas, Martin Tolstrup, Ole S. Søgaard, Bonaventura Clotet, Javier Martínez-Picado, Tomáš Hanke, Behazine Combadiere, Roger Paredes, Dennis Hartigan-O'Connor, Manel Esteller, Michael Meulbroek, María Luz Calle, Alex Sanchez-Pla, José Moltó, Beatriz Mothe, Christian Brander, Marta Ruiz-Riol
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2022-04-01
Serie:	EBioMedicine
Ämnen:	HIV-1 vaccine Epigenetics DNA methylation
Länkar:	http://www.sciencedirect.com/science/article/pii/S2352396422001402
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!